Loratadine should be used with caution in the treatment of patients with severe liver impairment.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
The administration of tablets should be discontinued at least 48 hours before skin tests, as antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.
Effects on ability to drive and use machines: In clinical trials that assessed driving ability, no impairment occurred In patients receiving loratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.
Use in Pregnancy: Pregnancy Category B: Loratadine was not found to be teratogenic in animal studies. There are no adequate and well-controlled studies in pregnant woman; use during pregnancy only if clearly needed.
Use in Lactation: Nursing Mothers: Loratadine and its (metabolite, descarboethoxyloratadine, pass easily into breast milk and achieve concentrations that are equivalent to plasma level with an AUCmilk/AUCplasma ratio of 1.17 and 0.85 for loratadine and descarboethoxyloratadine, respectively. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Caution should be exercised when Loratadine is administered to a nursing woman.
Use in Children: The safety and effectiveness of loratadine in children under 2 years of age have not been established.